Jyoti D. Patel
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
Purpose: ctDNA is a powerful diagnostic companion to tissue profiling. Tumor fraction (TF) is a global assessment of an individual’s ctDNA burden. We evaluated the impact of plasma TF on mutation detection and clinical outcomes in patients with previously treated, advanced non–small cell lung cancer on the Lung Master Protocol (Lung-MAP). Experimental Design: Paired tumor tissue and plasma were collected prospectively from patients on the Lung-MAP study. Plasma was collected within 30 days of a new biopsy with no intervening therapies. Tissue and ctDNA genomic profiling and ctDNA TF levels were assessed by Foundation Medicine. TF was primarily calculated from tumor aneuploidy, defaulting to fragmentomics and maximum somatic allele frequencies when aneuploidy was not detectable. The effect of TF on tissue–plasma mutation concordance, overall survival, and its relation to variant allele frequencies was assessed using linear regression, Lin's coefficient, and Cox modeling/log-rank testing. Results: A total of 194 patients were eligible for analysis. TF ≥1% was significantly associated with improved positive percent agreement between ctDNA and tissue across multiple alteration types with the exception of copy-number gains. For short variants, positive percent agreement improved from 51% when TF KRAS , STK11 , and TP53 —the three most common mutations. TF Conclusions: TF provides an accurate, clinically useful assessment of ctDNA plasma levels from patients with refractory, advanced non–small cell lung cancer. TF levels ≥1% are associated with significantly worse overall survival but improved mutation detection in liquid biopsies.
Year:
2025
Purpose: Acquired RET fusions have been reported at resistance to treatment with EGFR inhibitors in EGFR -mutant non–small cell lung cancer (NSCLC); however, a multicenter cohort of patients with EGFR -mutant lung cancers treated with osimertinib and selpercatinib for RET fusion–mediated osimertinib resistance has not previously been published. Patients and Methods: Patients who received selpercatinib in combination with osimertinib on a prospective expanded access clinical trial (NCT03906331) and single-patient compassionate use programs across five countries were centrally analyzed. All patients had advanced EGFR -mutant NSCLC with a RET fusion detected from tissue or plasma following osimertinib therapy. Clinicopathologic and outcomes data were collected. Results: Fourteen patients with EGFR -mutant and RET fusion–positive lung cancers who experienced prior progression on osimertinib received osimertinib and selpercatinib. EGFR exon 19 deletions (±T790M, 86%) and non- KIF5B fusions ( CCDC6-RET 50%, NCOA4-RET 36%) predominated. Osimertinib 80 mg daily and selpercatinib 80 mg twice daily were the most commonly administered dosages. The response rate, disease control rate, and median treatment duration were 50% [95% confidence interval (CI), 25%–75%, n = 12], 83% (95% CI, 55%–95%), and 7.9 months (range, 0.8–25+), respectively. Resistance was complex, involving EGFR on-target ( EGFR C797S), RET on-target ( RET G810S), and off-target ( EML4–ALK/STRN–ALK , KRAS G12S, BRAF V600E) mechanisms; RET fusion loss; or polyclonal mechanisms. Conclusions: For patients with EGFR -mutant NSCLC with an acquired RET fusion as a mechanism of EGFR inhibitor resistance, the addition of selpercatinib to osimertinib was feasible and safe and offered clinical benefit, supporting the prospective evaluation of this combination. See related commentary by Krebs and Popat, p. 2951
Year:
2025
Year:
2024
Purpose: Acquired RET fusions have been reported at resistance to treatment with EGFR inhibitors in EGFR-mutant non-small cell lung cancer (NSCLC), however, a multicenter cohort of patients with EGFR-mutant lung cancers treated with osimertinib and selpercatinib for RET fusion-mediated osimertinib resistance has not previously been published. Patients and methods: Patients who received selpercatinib in combination with osimertinib on a prospective expanded access clinical trial (NCT03906331) and single-patient compassionate use programs across five countries were centrally analyzed. All patients had advanced EGFR-mutant NSCLC with a RET fusion detected from tissue or plasma following osimertinib therapy. Clinicopathologic and outcomes data were collected. Results: Fourteen patients with EGFR-mutant and RET fusion-positive lung cancers who experienced prior progression on osimertinib received osimertinib and selpercatinib. EGFR exon 19 deletions (±T790M, 86%) and non-KIF5B fusions (CCDC6-RET 50%, NCOA4-RET 36%) predominated. Osimertinib 80mg daily and selpercatinib 80mg twice daily were the most commonly administered dosages. The response rate, disease control rate, and median treatment duration were 50% (95%CI 25%-75%, n=12), 83% (95%CI 55%-95%%), and 7.9 months (range 0.8-25+), respectively. Resistance was complex, involving EGFR on-target (EGFR C797S), RET on-target (RET G810S), and off-target (EML4-ALK/STRN-ALK, KRAS G12S, BRAF V600E) mechanisms, RET fusion loss, or polyclonal mechanisms. Conclusions: For patients with EGFR-mutant NSCLC with an acquired RET fusion as a mechanism of EGFR inhibitor resistance, the addition of selpercatinib to osimertinib was feasible, safe, and offered clinical benefit, supporting the prospective evaluation of this combination.
Year:
2024
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See complete disclaimer in Appendix 1 and Appendix 2 for more. Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline . PURPOSE To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer with driver alterations. METHODS This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized clinical trials (RCTs), with the latest time frame spanning February to October 2023. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts were convened. The literature search included systematic reviews, meta-analyses, and randomized controlled trials. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Eight new RCTs were identified in the latest search of the literature to date. RECOMMENDATIONS Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients based on targetable driver alterations. Additional information is available at www.asco.org/living-guidelines .
Year:
2024
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See complete disclaimer in Appendix 1 and Appendix 2 for more. Updates are published regularly and can be found at https://ascopubs.org/nsclc-non-da-living-guideline . PURPOSE To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer (NSCLC) without driver alterations. METHODS This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized clinical trials (RCTs), with the latest time frame spanning February to October 2023. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts were convened. The literature search included systematic reviews, meta-analyses, and randomized controlled trials. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Ten new RCTs were identified in the latest search of the literature to date. RECOMMENDATIONS Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients without driver alterations. Additional information is available at www.asco.org/living-guidelines .
Year:
2024
Collaborators (21)
Mark Awad
Chief, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
Jarushka Naidoo
Honorary Senior Lecturer
Royal College of Surgeons in Ireland
Joshua Reuss
Assistant Professor of Medicine
-
Erin Schenk
Assistant Professor
University of Colorado Anschutz Medical Campus
Balazs Halmos
Montefiore Medical Center
Alexander Drilon
Thomas Jefferson University Hospital
Jonathan W. Goldman
Associate Professor
UCLA
Karen Reckamp
Cedars-Sinai Medical Center
Saiama Waqar
Professor of Medicine
Washington University in St. Louis
Matthias Scheffler
University Hospital Bonn
Naoki Furuya
Ohio State University
Charu Aggarwal
University of Pennsylvania
Mary Redman
Fred Hutchinson Cancer Research Center
Lyudmila Bazhenova
University of California
Philip Mack
Senior Research Professor
Icahn School of Medicine at Mount Sinai
Hossein Borghaei
Professor and Chief, Thoracic Oncology
Fox Chase Cancer Center
Katie Minichiello
Fred Hutch Cancer Center
Karen Kelly
Professor of Medicine
University of California Davis Comprehensive Cancer Center
David R. Gandara
Co-Director, Center for Experimental Therapeutics in Cancer
University of California Davis Comprehensive Cancer Center
Helena A. Yu
Memorial Sloan Kettering Cancer Center
Dwight H. Owen
Ohio State University
Make your next move.
Prepare your application
Review drafts before you send them.